• Home
  • Biopharma
  • Will Veeva and Amgen’s $50 Billion Industry Push Set a New Global Standard for Technology-Driven Clinical Trials?
Image

Will Veeva and Amgen’s $50 Billion Industry Push Set a New Global Standard for Technology-Driven Clinical Trials?

Key Highlights:

  • Veeva Systems partners with Amgen to deploy its end-to-end Clinical Platform across global trials.
  • Collaboration aims to accelerate new medicine development by streamlining trial operations with advanced digital tools.
  • Marks a pivotal industry shift toward technology-driven clinical trial innovation, promising faster patient access to breakthrough therapies.

Collaboration to Accelerate Clinical Development
Veeva Systems announced a landmark collaboration with Amgen to transform clinical trial execution through the adoption of the Veeva Clinical Platform. By integrating this connected ecosystem across operations, Amgen aims to identify new efficiencies, improve trial oversight, and accelerate timelines for delivering novel treatments. This collaboration highlights how technology and biotech leadership are converging to advance medicine at scale.

Digital Backbone for End-to-End Trials
The Veeva Clinical Platform offers a comprehensive suite including CTMS, EDC, CDB, RTSM, eCOA, eTMF, Site Connect, and Study Training. Together, these tools create a unified data flow that streamlines every phase of a trial, from start-up through closeout. With automated processes and standardized workflows, Amgen expects to unlock new levels of agility while reducing operational complexity across its global research footprint.

Driving Innovation With Strategic Business Consulting
Beyond technology, Veeva Business Consulting will guide Amgen in implementation and change management, ensuring seamless integration into existing operations. This strategic support is expected to maximize value realization, enabling Amgen to deliver faster, smarter, and more patient-focused trials. The partnership reflects a shared vision to combine cutting-edge platforms with expert-driven transformation.

Company Commitments to Patients and Industry
For Amgen, the collaboration reinforces its mission of accelerating the development of medicines for serious diseases through innovation and scale. For Veeva, it further validates its role as the digital backbone of modern life sciences, trusted by more than 1,500 biopharma customers worldwide. Together, the two companies are setting a new industry benchmark for how advanced platforms can reshape the clinical trial ecosystem and ensure patients benefit sooner from medical breakthroughs.

About Veeva Systems
Veeva Systems (NYSE: VEEV) is a global leader in cloud-based solutions for the life sciences industry, delivering software, data, and business consulting that empower over 1,500 companies, from top biopharma to emerging biotech. As a Public Benefit Corporation, Veeva is committed to balancing customer success with stakeholder value, innovation, and industry transformation.

About Amgen
Amgen is one of the world’s leading biotechnology companies, focused on discovering, developing, and delivering innovative medicines that address serious diseases. With a robust pipeline and global presence, Amgen combines cutting-edge science with a commitment to patients, pioneering breakthroughs across oncology, immunology, and rare diseases.

Releated Posts

Will the US Health Agency Expand Coverage for GLP-1 Weight-Loss Drugs?

The U.S. Centers for Medicare & Medicaid Services (CMS) announced a new voluntary program to expand coverage of…

ByByAnuja Singh Dec 26, 2025

How is Bristol Myers Squibb Driving Growth After 2025’s Strategic Recalibration?

Bristol Myers Squibb (BMS) continues to build momentum in its post-loss-of-exclusivity strategy, with 2025 marked as a year…

ByByAnuja Singh Dec 26, 2025

Novartis Builds on a Track Record of Expansion Ahead of the 2026 J.P. Morgan Healthcare Conference

Basel, Switzerland Novartis closed 2025 with sustained operational momentum, building on its transformation into a pure-play innovative medicines…

ByByAnuja Singh Dec 26, 2025

Regeneron to Present at 44th Annual J.P. Morgan Healthcare Conference

TARRYTOWN, N.Y. – Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced today that it will webcast its presentation at the…

ByByAnuja Singh Dec 25, 2025

QALSODY® Shows Long-Term Benefits for SOD1-ALS Patients, Including Regained Strength and Extended Survival

Cambridge, Mass. Biogen Inc. (Nasdaq: BIIB) today announced that The Journal of the American Medical Association (JAMA) Neurology…

ByByAnuja Singh Dec 25, 2025

Can Jacobio Pharma and AstraZeneca Transform KRAS Cancer Treatment with $2 Billion Global Deal?

Shanghai/London Chinese biotech innovator Jacobio Pharma has entered a landmark global out-licensing agreement with AstraZeneca to advance its…

ByByAnuja Singh Dec 25, 2025

Is Samsung Biologics Set to Expand U.S. Operations with $280 Million GSK Acquisition?

Seoul/Washington, D.C. South Korea’s Samsung Biologics has announced its acquisition of its first U.S.-based drug production facility from…

ByByAnuja Singh Dec 25, 2025

Can TrumpRx and Pfizer’s Discount Deal Reshape Prescription Drug Pricing in the U.S.?

Washington, D.C. The U.S. administration has announced the launch of TrumpRx, a federally operated digital platform designed to…

ByByAnuja Singh Dec 25, 2025

Is Sanofi Strengthening Its Adult Vaccine Strategy with a $2.2 Billion Dynavax Deal?

Paris, France Sanofi has taken a major step to strengthen its adult vaccines portfolio by announcing a $2.2…

ByByAnuja Singh Dec 25, 2025
Scroll to Top